![Talha Badar: PrECOG 0905 Gilt vs Mido in ND FLT3m AML](https://oncodaily.com/pub/uploads/2024/11/78b6634e686d4ef0adaa12c3d2126ccc-e1731757348530.webp)
Talha Badar/X
Dec 10, 2024, 23:59
Talha Badar: PrECOG 0905 Gilt vs Mido in ND FLT3m AML
Talha Badar, Hematology/Oncology specialist in Mayo Clinic, shared a post on X:
“ASH24.
PrECOG 0905 Gilt vs Mido in ND FLT3m AML at ECOG-ACRIN Cancer Research Group.
PE: mutation MRD -ve composite CR.
Results: cCR was higher with Gilt (85.6 vs 72.4), however cCR with molecular MRD was NS post induction.
Inference: molecular MRD at later time point might worth exploring.”
More posts featuring Talha Badar.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 10, 2025, 18:24
Feb 10, 2025, 18:17
Feb 10, 2025, 16:49
Feb 10, 2025, 16:08
Feb 10, 2025, 15:56